Results 91 to 100 of about 68,946 (284)

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

Haematologica, 2011
Background Point mutations of the BCR-ABL tyrosine kinase domain are considered the predominant cause of imatinib resistance in chronic myeloid leukemia.
Benjamin Hanfstein, Martin C. Müller, Sebastian Kreil, Thomas Ernst, Thomas Schenk, Christian Lorentz, Uwe Schwindel, Armin Leitner, Rüdiger Hehlmann, Andreas Hochhaus   +9 more
doaj   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source

Imatinib decreases germ cell survival and germline stem cell proliferation in rodent testis ex vivo and in vitro

Andrology, EarlyView.
Abstract Background Imatinib and dasatinib are tyrosine kinase inhibitors (TKIs) increasingly used to treat several diseases in both children and adults at fertile age. We have previously shown that imatinib has adverse effects on developing testis, and imatinib‐treated male patients have been reported to have reduced sperm counts.
Anna Eggert, Sini Laasanen, Mirja Nurmio, Aida Wahlgren, Kirsi Jahnukainen, Kim Eerola, Miisael Nieminen, Opeyemi Olotu, Noora Kotaja, Juho‐Antti Mäkelä, Jorma Toppari   +10 more
wiley   +1 more source

In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABLKinase Inhibitor [PDF]

, 2017
BACKGROUND: The leukemia cells of approximately 95% of patients with chronic myeloid leukemia and 30%-50% of adult patients with acute lymphoblastic leukemia express the Bcr/Abl oncoprotein, which is the product of a fusion gene created by a chromosomal ...
Buchdunger, Elisabeth, Cleris, Loredana, Formelli, Franca, Gambacorti-Passerini, Carlo, Giardini, Roberto, le Coutre, Philipp, Marchesi, Edoardo, Mologni, Luca   +7 more
core  

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks [PDF]

, 2011
The resistance of leukemic stem cells in response to targeted therapies such as tyrosine kinase inhibitors (TKIs) relies on the cooperative activity of multiple signaling pathways and molecules, including TGFβ, AKT, and FOXO transcription factors ...
Austin, Bernardi, Bhatia, Brunet, Carayol, Chen, Chen, Druker, Duy, Fernández de Mattos, Francesca Pellicano, Graham, Hurtz, Ilaria, Ito, Komatsu, Lee, Mahon, Naka, Neubauer, Neviani, Neviani, Peng, Rowley, Samanta, Stambolic, Tessa L. Holyoake, Tothova, Xie, Yilmaz, Zhou   +30 more
core   +2 more sources

Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Therapy for Rectal Cancer: Cost Analysis in a Public Healthcare System

ANZ Journal of Surgery, EarlyView.
Costs of neoadjuvant therapy. ABSTRACT Purpose Total neoadjuvant therapy (TNT) has become the standard of care in locally advanced rectal cancer, but its economic impact is unclear. This study compares the cost of TNT with conventional neoadjuvant therapy (CNT), consisting of either short‐course radiotherapy or long‐course chemoradiotherapy, within a ...
Ishraq Murshed, Sergei Bedrikovetski, Ishmam Murshed, Zachary Bunjo, Tracy Fitzsimmons, Michelle Thomas, Tarik Sammour   +6 more
wiley   +1 more source

BCR‐ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph+ ALL

Cancer Medicine, 2018
Philadelphia chromosome (Ph)/BCR‐ABL‐positive (ph+) ALL is the most common genetic abnormality associated with ALL and has been shown to confer the worst prognosis to both children and adults.
Wen‐bin Cao, Jian‐feng Yao, Si‐zhou Feng, Yi He, Er‐lie Jiang, Rong‐li Zhang, Dong‐lin Yang, Ming Gong, Xiao‐hui Zheng, Shu‐lian Chen, Jia‐li Sun, Lu‐kun Zhou, Ming‐zhe Han   +12 more
doaj   +1 more source

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.

Blood, 2004
The outcome for adult patients with BCR-ABL-positive acute lymphoblastic leukemia (ALL) remains dismal and long-term survival can hardly be achieved except by allogeneic hematopoietic stem cell transplantation (HSCT). The Japan Adult Leukemia Study Group
M. Towatari, M. Yanada, N. Usui, J. Takeuchi, I. Sugiura, M. Takeuchi, F. Yagasaki, Y. Kawai, S. Miyawaki, S. Ohtake, I. Jinnai, K. Matsuo, T. Naoe, R. Ohno   +13 more
semanticscholar   +1 more source

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

British Journal of Haematology, EarlyView.
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu, Xipeng Yue, Xinrong Zhan, Xiaojuan Liu, Hongxia Ma, Fuli Qin, Lijuan Duan, Hongmian Zhao, Yan Zhang, Shiqiang He, Huifang Zhao, Chunlei Zhang, Xiangke Xin, Wenli Zhang, Yongping Song, Bingcheng Liu, Weiming Li, Yanli Zhang   +17 more
wiley   +1 more source

RAPSYN-mediated neddylation of BCR-ABL alternatively determines the fate of Philadelphia chromosome-positive leukemia

eLife
Philadelphia chromosome-positive (Ph+) leukemia is a fatal hematological malignancy. Although standard treatments with tyrosine kinase inhibitors (TKIs) have achieved remarkable success in prolonging patient survival, intolerance, relapse, and TKI ...
Mengya Zhao, Beiying Dai, Xiaodong Li, Yixin Zhang, Chun Qiao, Yaru Qin, Zhao Li, Qingmei Li, Shuzhen Wang, Yong Yang, Yijun Chen   +10 more
doaj   +1 more source